Polygonatum sibiricum polysaccharide attenuates bone marrow-derived macrophages to differentiate into osteoclasts and protects against lipopolysaccharide-induced osteolysis in vivo

doi:10.3969/j.issn.2095-4344.2017.20.001

Abstract

Abstract:

BACKGROUND: Bone marrow-derived mononuclear cells (BM-MNCs) hold the potential of differentiating into osteoclasts. Polygonatum sibiricum polysaccharide (PSP) may inhibit the differentiation of BM-MNCs into osteoclasts and it is expected to become a new drug for the treatment of osteoporosis.
OBJECTIVE: To investigate the effect of PSP on the differentiation of mouse BM-MNCs into osteoclasts induced by receptor activator of nuclear factor kappa-B ligand (RANKL) and bone resorption in vivo.
METHODS: Mouse bone marrow-derived macrophages cultured in vitro, the effect of macrophage colony stimulating factor and PSP (5, 10, 20, 40, 80,160, 320, 640, 1 280, 2 560 mg/L) on the proliferation of mouse BM-MNCs was detected by cell counting kit-8 assay to determine the PSP concentration range; the mouse BMMs were cultured and induced in DMEM medium containing macrophage colony stimulating factor, RANKL and 5, 10, 20, 40, 80,160, 320, 640 mg/L PSP, respectively; those cultured without PSP served as control group. The morphological changes of cells were observed under an inverted microscope.; the number of osteoclasts was detected by tartrate-resistant acid phosphatase staining; the mRNA expression levels of osteoclast-related genes including tartrate-resistant acid phosphatase, matrix metalloproteinase-9, cathepsin K, and nuclear factor of activated T cells c1 were evaluated by quantitative real-time PCR. A mouse model of calvarial osteolysis induced by lipopolysaccharide was established to receive PSP intervention, and then micro CT scanning, three-dimensional reconstruction and relevants software were used for quantitative analysis of bone volume/volume percentage, trabecular number, trabecular bone spacing and thickness. The number of osteoclasts was identified by tartrate-resistant acid phosphatase staining and quantitative analysis of bone resorption area was conducted.
RESULTS AND CONCLUSION: Compared with the control group, the concentration of PSP below 640 mg/L showed no significant effect on the proliferation of BMMs (P > 0.05). Different concentrations of PSP (40-640 mg/L) significantly reduced the number of osteoclasts, osteoclast differentiation and maturation, and the mRNA expression levels of tartrate-resistant acid phosphatase, matrix metalloproteinase-9, cathepsin K, and nuclear factor of activated T cells c1 TRAP, MMP-9, CtsK and NFATc1 (P < 0.05). Compared with lipopolysaccharide, PSP could effectively alleviate the lipopolysaccharide-induced calvarial osteolysis, and the bone volume/volume percentage, trabecular number, and trabecular bone spacing were significantly decreased (P < 0.05); additionally, the number of osteoclasts and the area of bone resorption were decreased significantly (P < 0.01). To conclude, PSP can inhibit the differentiation and maturation of mouse BMMs to osteoclasts and alleviate lipopolysaccharide-induced calvarial osteolysis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Polygonatum, Cell Differentiation, Osteoclasts, Osteoporosis, Tissue Engineering

CLC Number:

R318

He Ji-chen1, Zong Shao-hui1, Zeng Gao-feng2, Du Li1, Peng Xiao-ming1, Shi Xiong-zhi1, Wu Yun-le1. Polygonatum sibiricum polysaccharide attenuates bone marrow-derived macrophages to differentiate into osteoclasts and protects against lipopolysaccharide-induced osteolysis in vivo[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(20): 3117-3122.

Figures/Tables 3

References

[1] Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.

[2] TanakaY, Nakayamada S, Okada Y.Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy.2005; 4(3): 325-328.

[3] Hayashi M, Nakashima T, Taniguchi M, et al.Osteoprotection by semaphorin 3A. Nature.2012; 485(7396): 69-74.

[4] 曾祥周.青蒿琥酯对破骨细胞的作用和分子机制研究[D].南方医科大学, 2015.

[5] Hennemann A.[Osteoporosis: prevention, diagnosis and therapy]. Med Monatsschr Pharm.2002;25(5):164-167.

[6] Beard MK. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Curr Med Res Opin.2012; 28(1):141-147.

[7] 雷震,杨光义,叶方,等.黄精多糖药理作用及临床应用研究概述[J].中国药师,2012,15(1):114-116.

[8] 何才通,李文.黄精多糖药理功效研究进展[J].新中医,2014,46(3): 196-199.

[9] 胡敏,王琴,周晓东,等.黄精药理作用研究进展及其临床应用[J].广东药学, 2005,15(5):68-71.

[10] 曾高峰,宗少晖,邹斌,等.黄精多糖对小鼠骨髓间充质干细胞向成骨细胞分化中ALP和BGP表达的影响[J].中国骨质疏松杂志, 2014,20(7):779-783.

[11] 曾高峰,宗少晖,邹斌,等.黄精多糖对小鼠骨髓间充质干细胞向成骨细胞分化中PINP和BMP-2表达的影响[J].天然产物研究与开发,2014,26(8): 1188-1192.

[12] 农梦妮,曾高峰,宗少晖,等.黄精多糖调控骨髓间充质干细胞向成骨细胞分化[J].中国组织工程研究,2016,20(15):2133-2139.

[13] Udagawa N,Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone.1999; 25(5):517-523.

[14] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.

[15] Feng X. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene.2005;350(1):1-13.

[16] Fujikawa Y, Quinn JM,A. Sabokbar A, et al. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology.1996;137(9):4058-4060.

[17] Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res.2013;28(4):711-722.

[18] Akchurin T, Aissiou T, Kemeny N, et al. Complex dynamics of osteoclast formation and death in long-term cultures. PLoS One. 2008; 3(5):e2104.

[19] Zhang H, Ricciardi BF, Yang X, et al. Polymethylmethacrylate particles stimulate bone resorption of mature osteoclasts in vitro. Acta Orthop. 2008; 79(2):281-288.

[20] Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature.1999; 397(6717):315-323.

[21] Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103(1): 41-50.

[22] Sundaram K, Nishimura R, Senn J, et al. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res. 2007; 313(1):168-178.

[23] Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009; 6(10):587-595.

[24] 吕明波.淫羊藿苷对体外培养破骨细胞影响的实验研究[D].兰州大学,2007.

[25] 张毅.阿司匹林对大鼠破骨细胞分化成熟及RANK基因表达的影响[D].第四军医大学,2013.

[26] 王霖,毛昱嘉,王文杰.双醋瑞因对破骨细胞性骨破坏的抑制作用及机制[J].药学学报,2006,41(6):555-560.

[27] 贺龙刚.青藤碱对RANKL和LPS诱导的破骨细胞的影响及作用机制研究[D].南方医科大学, 2013.

[28] 刘铭,张健,陈婷梅,等.低强度超声对颅骨溶解模型小鼠磨损颗粒诱导的骨溶解效应的影响[J].吉林大学学报(医学版),2013,55(2): 304-307+429.